POLYMORPHIC FORMS OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE
申请人:Merck Patentgesellschaft
公开号:US20170182037A1
公开(公告)日:2017-06-29
The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
本发明涉及1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐的新晶体形态、1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪双盐酸盐的晶体形态以及非晶态1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨基甲酰苯并呋喃-5-基)-哌嗪盐酸盐,特别适用于制备用于治疗或预防抑郁症、焦虑症、双相障碍、躁狂、痴呆、物质相关障碍、性功能障碍、进食障碍、肥胖症、纤维肌痛、睡眠障碍、精神障碍、脑梗塞、紧张,用于治疗高血压、脑部疾病、慢性疼痛、肢端肥大症、性腺功能减退症、继发性闭经、经前综合征以及不良产褥期泌乳的副作用疗法。